Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Can you apply?
This grant is for research investigators studying the mechanisms by which incretin mimetics may impact cancer risk. Eligible applicants include principal investigators at domestic and international research institutions, including universities, medical schools, and research hospitals. The R21 mechanism is designed for exploratory and developmental research; clinical trials are not allowed under this funding opportunity. Applicants must have an active institutional research office and comply with federal research compliance requirements. The research must address fundamental questions about the biological or pharmacological mechanisms linking incretin mimetics to cancer outcomes, rather than testing therapeutic interventions directly in patient populations.
This grant is for research investigators studying the mechanisms by which incretin mimetics may impact cancer risk. Eligible applicants include principal investigators at domestic and international research institutions, including universities, medical schools, and research hospitals. The R21 mechanism is designed for exploratory and developmental research; clinical trials are not allowed under this funding opportunity. Applicants must have an active institutional research office and comply with federal research compliance requirements. The research must address fundamental questions about the biological or pharmacological mechanisms linking incretin mimetics to cancer outcomes, rather than testing therapeutic interventions directly in patient populations.
Program description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Researcher (independent)
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Details
This grant is for research investigators studying the mechanisms by which incretin mimetics may impact cancer risk. Eligible applicants include principal investigators at domestic and international research institutions, including universities, medical schools, and research hospitals. The R21 mechanism is designed for exploratory and developmental research; clinical trials are not allowed under this funding opportunity. Applicants must have an active institutional research office and comply with federal research compliance requirements. The research must address fundamental questions about the biological or pharmacological mechanisms linking incretin mimetics to cancer outcomes, rather than testing therapeutic interventions directly in patient populations.
How to apply
Application links
Required documents
- NIH Application Form (SF-424 equivalent, now via eRA Commons in NIH format)
- Project Narrative (limited to 6 pages for R21)
- Research Strategy (including Significance, Innovation, and Approach sections)
- Biographical Sketch(es) for PI and key personnel (5-page limit)
- Budget and Budget Justification
- Institutional Commitment/Facilities & Administrative Resources
- Letters of Support from collaborating institutions or co-investigators (if applicable)
- Vertebrate Animal or Human Subjects sections (if applicable, including IRB/IACUC approvals)
- Data Management Plan (increasingly required by NIH)
- Conflict of Interest Disclosures
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.393 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$213,206,023
-
$56,551,552
-
$48,640,472
-
$47,009,863
-
$42,878,192
-
$37,448,862
-
$29,324,004
-
$26,395,336
-
$24,427,436
-
$23,149,727
Top States by Funding
- MA 10 awards $373.4M
- CA 10 awards $259.2M
- MN 4 awards $106.9M
- NY 7 awards $98.1M
- TN 7 awards $97.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.393). How funding has trended year over year.
| 2024 | $754,945,159 | |
| 2025 | $834,514,512 | |
| 2026 est. | $520,096,276 |
FAQ
Who is eligible to apply for this R21 grant?
Principal investigators at research institutions (academic medical centers, universities, research hospitals, etc.) with strong research credentials and institutional infrastructure. Both early-career and established investigators can apply.
Are clinical trials allowed under this funding opportunity?
No. This R21 specifically excludes clinical trials. The focus is on mechanistic research using laboratory, translational, or observational study designs.
What types of research activities are supported?
Exploratory and developmental research investigating how incretin mimetics affect cancer risk through basic science, translational research, or mechanistic studies. This may include cell culture, animal models, bioinformatics, or molecular pathway analysis.
What is the typical funding range and project duration?
R21 grants typically provide $150,000–$275,000 total costs (direct + indirect) over 2 years. Actual amounts vary by institute.
How competitive is this funding opportunity?
R21 mechanisms are moderately competitive. Success depends on novel mechanistic insights, rigorous study design, and clear relevance to cancer risk and diabetes management.
💡 Tips for applicants
- Frame your research as exploratory and mechanism-focused. R21 reviewers look for novel hypotheses and preliminary data suggesting a plausible link between incretin mimetics and cancer outcomes, not large-scale efficacy studies.
- Clearly articulate the biological or pharmacological mechanism you are investigating (e.g., effects on cell proliferation, metabolic pathways, immune function, or pancreatic β-cell biology).
- Address why current knowledge about incretin mimetics and cancer is insufficient, and explain how your mechanistic findings could inform future clinical or public health research.
- Use preliminary data strategically. Even modest pilot data strengthens an R21 application and demonstrates feasibility of your proposed approach.
- Ensure your study design genuinely rules out clinical trial components—reviewers will reject applications that essentially describe small clinical studies disguised as mechanistic research.
⚠️ Common mistakes
Applicants often submit clinical trial designs or patient outcome studies, which violate the R21 clinical trial exclusion and result in desk rejection. Another common pitfall is proposing research questions that are too broad or unfocused; R21 reviewers expect clear, testable mechanistic hypotheses with a narrower scope than R01 grants. Finally, insufficient preliminary data or failure to articulate preliminary evidence supporting the feasibility of the proposed work significantly weakens competitiveness.
Similar grants
- ROLLING Underground Storage Tank Cleanup Fund — State Water Resources Control Board (California)
- CLOSED Central Valley Tributaries — Department of Water Resources (California)
- CLOSED Multifamily Housing Program (MHP) — Department of Housing and Community Development (California)
- CLOSED Water Desalination Grant Program — Department of Water Resources (California)
- CLOSED 2021 Noxious Weed Grant Program — CA Department of Food and Agriculture (California)